CalPERS invested $718 million with four private equity funds in February, according to recently released data on the pension fund’s website. The fund invested $368 million with KKR European Fund III, $150 million with CVC Capital Partners Asia Pacific III, $125 million with Essex Woodlands Health Ventures Fund VIII and $75 million with Clarus Lifesciences II.
The $240.1 billion California Public Employees’ Retirement System, Sacramento, also doled out $153.3 million to nine domestic equity emerging managers in January. AH Lisanti Capital Growth received $14.7 million for small-cap growth; Atlanta Life Investment Advisors, $15.8 million for large-cap value; DSM Capital Partners, $14.9 million for large-cap growth; Mastrapasqua Asset Management, $15 million for large-cap growth; and Moody Aldrich Partners, $15.8 million for all-cap value. OakBrook Investments received $15.2 million for large-cap core and $15.5 million for midcap core; Paradigm Asset Management, $15.5 million for large-cap value; Profit Investment Management, $15.5 million for small-cap core; and Rushmore Investment Advisors, $15.4 million for a large-cap growth.
Separately, CalPERS received support from Egan-Jones, Glass Lewis, RiskMetrics Group and Proxy Governance for its call to give Eli Lilly & Co. shareholders the right to amend company bylaws by majority vote, according to a news release. Shareholders now cannot institute bylaw amendments. CalPERS owns 4.8 million shares of Eli Lilly worth more than $265 million. Lilly spokesman Philip Belt said the proposal could give large shareholders the ability to change bylaws to advance their own special interests. The Eli Lilly board opposes the change. The proposal is on the proxy card as a non-binding resolution to be discussed at the company’s April 21 annual meeting.
